Vectarion International Multicentre Study (VIMS): a long term double blind placebo controlled trial in COLD patients.

Vectarion International Multicentre Study (VIMS): a long term double blind placebo controlled trial in COLD patients. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Vectarion International Multicentre Study (VIMS): a long term double blind placebo controlled trial in COLD patients. Abstract Text:

P Sadoul,

In a previous six month study almitrine bismesylate ( Vectarion ) administration has been shown to be effective and safe in the treatment of hypoxaemic and hypercapnic chronic obstructive pulmonary disease (COLD). The protocol of the present VIMS study has been designed to complete the evaluation of the clinical benefit obtained after oral almitrine bismesylate administration on a larger scale and over at least a one year period in hypoxaemic COLD patients. Male and female outpatients will be included with an age 35-75, weight 50-95 kg, PaO2 45-65 mmHg, PaCO2 35-60 mmHg, FEV1/FVC 30-65%. Patients with primarily restrictive pulmonary disease, with cardiac, renal, central nervous system or hepatic impairment, and female patients of child bearing potential, will be excluded. After a three week stabilization period, patients will enter the study and receive on a random basis either almitrine bismesylate or placebo with a stratified allocation within each centre and whether patients receive or not long term continuous domiciliary oxygen therapy. Clinical examination, arterial blood gases, dyspnoea score, 6 mn walking distance, pulmonary function tests, haematological, biochemical profiles and plasma levels will be measured on a quarterly basis and electrocardiogram at six monthly intervals. Hospitalizations, new signs and symptoms, and changes in concomitant treatment will be recorded at each visit. Administration of the drug will be 50 mg b.d. during the first three months with a possible increase of 50 mg after the third and/or the sixth month visits if, and only if, PaO2 increase is less than 5 mmHg and if the drug is well tolerated.(ABSTRACT TRUNCATED AT 250 WORDS)

Vectarion International Multicentre Study (VIMS): a long term double blind placebo controlled trial in COLD patients. Publishing Authors By Initials

P Sadoul,

For similar heterocyclic compounds: heterocyclic compounds, 1-ring: piperazines research abstracts see: heterocyclic compounds: heterocyclic compounds, 1-ring: piperazines research

PUBMED ID PMID:

MEDLINE DATE:

Vectarion International Multicentre Study (VIMS): a long term double blind placebo controlled trial in COLD patients. Journal Published:

PUBLICATION TYPE: Randomized Controlled Trial

Journal: European journal of respiratory diseases. Suppleme

VOLUME: 126

Page Numbers: 357-61

Journal Abbreviation:

ISSN: 0106-4347

DAY: 21

MONTH: 02

YEAR: 1983

Vectarion International Multicentre Study (VIMS): a long term double blind placebo controlled trial in COLD patients. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 8010618

Vectarion International Multicentre Study (VIMS): a long term double blind placebo controlled trial in COLD patients. Keywords Mesh Terms:

KEYWORDS: Piperazines

MESH TERMS: therapeutic use

Chemical & Substance for Abstract: Vectarion International Multicentre Study (VIMS): a long term double blind placebo controlled trial in COLD patients. Information

Substance Name: Almitrine

Registry Number: 27469-53-0

Grant and Affiliation Information for Vectarion International Multicentre Study (VIMS): a long term double blind placebo controlled trial in COLD patients.

AFFILIATION:

Country: DENMARK

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Eur J Respir Dis Suppl

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Vectarion International Multicentre Study VIMS: a long term double blind placebo controlled trial in COLD patients Related Publications

• Alix differs from ESCRT proteins in the control of autophagy.
• Design and Synthesis of Cyclopeptide Analogues of the Potent Histone Deacetylase Inhibitor FR235222.
• Drug effects on viscoelasticity of mucus.
• Pneumoconiosis in Europe yesterday, today and tomorrow.
• Role of the rheological properties of bronchial secretions in the mucociliary transport at the bronchial surface.
• The frog palate for studying mucus transport velocity and mucociliary frequency.
• Vectarion International Multicentre Study (VIMS): a long term double blind placebo controlled trial in COLD patients.
• [A PARTICULAR TYPE OF FUNCTIONAL RENAL INSUFFICIENCY: HYPOXIC GLOMERULO-NEPHROPATHY.]
• [PLACE OF ANALEPTICS IN RESPIRATORY PATHOLOGY.]
• [TREATMENT OF BRONCHIAL SUPERINFECTION OUTBREAKS IN CHRONIC BRONCHITIS PATIENTS WITH PENIMEPICYCLINE.]